drugset
drugset / Trial / NCT04707209

Sirolimus for Retinal Astrocytic Hamartoma

NCT04707209 ↗

Completed 1 enrolled The Hospital for Sick Children
NaSingle-groupOpen-labelTreatment

Summary

A single patient study using intravitreal Sirolimus to treat a patient with multiple retinal astrocytic hamartomas (RAH) of both eyes.

Timeline

Start
2020-11-04
Primary completion
2024-03-22
Completion
2024-03-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 0.02 ml Intravitreal

Indications

No indication recorded.